NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis $0.85 -0.03 (-3.73%) (As of 11:07 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Bio-Path Stock (NASDAQ:BPTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bio-Path alerts:Sign Up Key Stats Today's Range$0.85▼$0.8850-Day Range$0.85▼$1.1952-Week Range$0.80▼$12.40Volume20,940 shsAverage Volume1.14 million shsMarket Capitalization$2.17 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company OverviewBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Read More… Post-Election Bitcoin Warning (Ad)According to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months... Click here to see Dan's full warning (and his potential solution) Bio-Path Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreBPTH MarketRank™: Bio-Path scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBio-Path has received no research coverage in the past 90 days.Read more about Bio-Path's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($6.20) to ($4.04) per share.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bio-Path's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.10% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently decreased by 79.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.10% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently decreased by 79.98%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.72 News SentimentBio-Path has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bio-Path this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.72% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions.Read more about Bio-Path's insider trading history. Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address BPTH Stock News HeadlinesStockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)November 12 at 1:45 AM | americanbankingnews.comBio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024November 8, 2024 | globenewswire.comPost-Election Bitcoin WarningAccording to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months... November 14, 2024 | Stansberry Research (Ad)Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesOctober 10, 2024 | globenewswire.comNano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood CancerOctober 10, 2024 | finance.yahoo.comBio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...October 10, 2024 | finance.yahoo.comBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesOctober 8, 2024 | globenewswire.comBio-Path Holdings Initiates Development of Therapeutic Program for Treatment of ObesityOctober 8, 2024 | globenewswire.comSee More Headlines BPTH Stock Analysis - Frequently Asked Questions How have BPTH shares performed this year? Bio-Path's stock was trading at $9.26 at the beginning of the year. Since then, BPTH stock has decreased by 90.8% and is now trading at $0.8510. View the best growth stocks for 2024 here. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Thursday, August, 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts' consensus estimates of ($1.54) by $0.38. When did Bio-Path's stock split? Shares of Bio-Path reverse split on Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), Micron Technology (MU), Anavex Life Sciences (AVXL) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings8/15/2024Today11/13/2024Next Earnings (Confirmed)11/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Price Target and Rating Average Stock Price Target$20.00 High Stock Price Target$20.00 Low Stock Price Target$20.00 Potential Upside/Downside+2,162.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,842.40% Return on Assets-306.66% Debt Debt-to-Equity RatioN/A Current Ratio1.67 Quick Ratio1.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book1.25Miscellaneous Outstanding Shares2,550,000Free Float2,534,000Market Cap$2.25 million OptionableOptionable Beta0.22 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:BPTH) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.